Pharmaceutical behemoths Novo Nordisk and Eli Lilly are engaged in intense competition in the rapidly growing market for weight-loss medications. The argument in this dispute is gradually shifting from efficacy to pharmacy availability as both companies are having difficulty keeping up with the high demand for their individual drugs.
Since its December 2023 launch, Eli Lilly’s Zepbound has quickly risen to a significant 40% market share, with almost 130,000 prescriptions written as of mid-July. This is a noteworthy accomplishment considering that Wegovy, the more seasoned rival from Novo Nordisk, requires roughly 200,000 prescriptions per week. Zepbound has a minor advantage over the other in terms of typical weight reduction results, but both medications are severely lacking in supply, which affects their accessibility.
